title: A new approach to prostate cancer.
abstract: Growth of androgen-dependent human prostatic adenocarcinoma implanted in the nude mouse (Honda tumour), is inhibited by 6-methyleneprogesterone. This steroid is a potent inhibitor of both rat and human prostatic 5 alpha-reductase in-vitro. In-vivo, at the studied dose level, it reduces metabolic conversion of testosterone to dihydrotestosterone with minimal effects upon circulating LH and testosterone. These data support the hypothesis that dihydrotestosterone and not testosterone is the main trophic androgen of the human prostatic neoplasm.
authors.affiliation: College of Medical Care and Technology, Gunma University, Department of Pathology, Gunma University School of Medicine, Japan.
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Nakazato
authors.forename: V
authors.initials: V
authors.lastname: Petrow
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009929:Organ Size / Q000187:drug effects; D011374:Progesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011467:Prostate / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D012669:Seminal Vesicles / Q000187:drug effects
chemical_list: C036790:6-methylene-4-pregnene-3,20-dione; D011374:Progesterone